MENU
 JPMA
  • Directions
  • Japanese
  • About JPMA

    About JPMA: Top

    • Message from the President
    • Overview of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • About Medicines

    About Medicines: Top

    • Medication Guide for the General Public
    • Clinical Trial Information
    • Working Together with Patients
  • Committee Updates

    Committee News Top

    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R & D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • Newsletter
  • Newsroom

    Newsroom Top

    • News Releases and Announcements
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA Video Content and Advertisements
  • The Office of Pharmaceutical Industry Research
Close
 JPMA

Return to Top

  • Patients and the General Public (About Medicines)
    Patients and the General Public (About Medications) Top
    • Medication Guide for the General Public
    • Clinical Trial Information
    • Working Together with Patients
  • Committee Updates
    Committee News Top
    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R & D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • About JPMA
    About JPMA: Top
    • Message from the President
    • Overview of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • Policies and Activities
    Policies & Activities Top
    • Business Policy, Business Plan, and Implementation Plan
    • Committee Activities
    • Convention on Biological Diversity
  • Voluntary Standards
    Voluntary Standards Top
    • Code of Conduct
    • JPMA Code of Practice
    • Transparency Guideline for the Relation between Corporate Activities and Medical Institutions
    • Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations
    • Guidelines for the Preparation of Summaries of Product Characteristics for Prescription Drugs (Abbreviation: Preparation Guidelines)
    • Clinical Research
    • Basic Principles and Guidelines for Action on Biodiversity
    • Guidelines on Fair Competition at Meetings of the Japan Pharmaceutical Manufacturers Association
    • Agreements, Manuals, and Guidelines
  • Newsroom
    Newsroom Top
    • News Releases and Announcements
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA Video Content and Advertisements
  • The Office of Pharmaceutical Industry Research  Opens in a new window
  • Social Media Policy
  • Website Terms of Use
  • Access
  • Japanese
  • Home
  • Committee Updates
  • Intellectual Property Committee
  • Intellectual Property System

Intellectual Property Committee Intellectual Property System

  • May 18, 2026 Recent Judicial Decisions on the Operation of the Patent Term Extension System and the Committee's Position on the Approval of Generic Drugs
  • December 02, 2024 "Article on the WIPO Treaty on GRATK in the November issue of JIPA's "Intellectual Property Management" magazine
  • Apr 26, 2021 IP PACT: (IP Principles for Advancing Cures and Therapies)
  • Aug 21, 2017 IP High Court Grand Panel Decision in Oxaliplatinum Case (142KB)
  • Apr 14, 2015 Opinion on the IP High Court Grand Panel Decision on Patent Term Extension (Part 2) (81KB)
  • 05 Jan 2015 Opinion on the Dissenting Judgment of the Intellectual Property High Court regarding Patent Right Duration Extension (133KB)
  • 30 Jul 2014 Opinion on the fundamental review of the system of employee inventions (512KB)
  • Feb 26, 2014 Opinion of Industry (IPMA, JPMA, and JEITA) on the Opinion of Industry on Employee Inventions (75KB)
  • Mar 05, 2013 Contribution to Global Health from Intellectual Property Aspects (77KB)
  • 2013/03/05 JPMA's Contribution to Global Health from an Intellectual Property Perspective (15KB)
  • 05 Nov 2010 Opinion on the Harmonization of Intellectual Property Systems in Canada and the EU (432KB)

Share this page

  • Post
  • Share

TOP

Site Search

  • Home
  • Committee Updates
  • Intellectual Property Committee
  • Intellectual Property System
  • JPMA PR and Communications Activities
  • Pharmaceutical Research Institute
  • List of Non-Financial Information Disclosures by Member Companies
  • STOP AMR
  • About the JPMA
  • Policies and Activities
  • Voluntary Standards
  • Global Health
  • Newsroom
  • Patients and the General Public (About Medicines)
  • Clinical Trial Information
  • Committee Updates
  • JapanesePage will open in a new window.
  •  x
  •  Facebook
  •  YouTube
  • Site Map
  • Website Terms of Use
  • Basic Policy on Information Security
  • Social Media Policy
  • Links
  • Accessibility Policy
  • PRAISE-NET Login

© Japan Pharmaceutical Manufacturers’
’ Association (JPMA). All rights reserved.

Notification

This website uses automatic translation.
The translated content may not always be fully consistent with the original Japanese content.